Skip to Main Content

Paper Details

Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity <i>Ex Vivo and In Vivo</i>.
J Virol
14
2021
AKT, CD8+, CD8+ T, GSK-3i, HIV, HIV-1, NK cell, NK cells, SB-216763, SIV, T cell, aviremic, cytotoxic T lymphocytes, glycogen synthase kinase-3, mTOR, rhesus macaques, rhesus monkeys, tideglusib
Author NameAffiliation
Andrea GramaticaGladstone Institute of Virology, Gladstone Institutes
Andrea GramaticaUniversity of California san francisco
Roland SchwarzerGladstone Institute of Virology, Gladstone Institutes
Roland SchwarzerUniversity of California san francisco
William BrantleyVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Benjamin Varco-MerthVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Hannah S SperberVitalant Research Institute
Hannah S SperberFree University of Berlin, Institute of Biochemistry
Philip A HullGladstone Institute of Virology, Gladstone Institutes
Mauricio MontanoGladstone Institute of Virology, Gladstone Institutes
Stephen A MiguelesNational Institute of Allergy and Infectious Diseases, National Institutes of Health
Daniel RosenthalNational Institute of Allergy and Infectious Diseases, National Institutes of Health
Louise E HoganUniversity of California san francisco
Jeffrey R JohnsonGladstone Institute of Virology, Gladstone Institutes
Jeffrey R JohnsonUniversity of California san francisco
Thomas A PackardGladstone Institute of Virology, Gladstone Institutes
Zachary W GrimmettGladstone Institute of Virology, Gladstone Institutes
Eytan HerzigGladstone Institute of Virology, Gladstone Institutes
Eytan HerzigUniversity of California san francisco
Emilie BesnardGladstone Institute of Virology, Gladstone Institutes
Michael NekorchukVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Feng HsiaoGladstone Institute of Virology, Gladstone Institutes
Feng HsiaoUniversity of California san francisco
Steven G DeeksUniversity of California san francisco
Steven G DeeksUniversity of California san francisco
Michael SnapeAMO Pharma Ltd.
Bernard KiernanAMO Pharma Ltd.
Nadia R RoanGladstone Institute of Virology, Gladstone Institutes
Nadia R RoanUniversity of California san francisco
Jeffrey D LifsonInc., Frederick National Laboratory for Cancer Research
Jacob D EstesVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Louis J PickerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Eric VerdinGladstone Institute of Virology, Gladstone Institutes
Eric VerdinUniversity of California san francisco
Eric VerdinUniversity of California san francisco
Nevan J Krogan (CM4AI)University of California san francisco
Nevan J Krogan (CM4AI)Gladstone Institute of Virology, Gladstone Institutes
Timothy J HenrichUniversity of California san francisco
Mark ConnorsNational Institute of Allergy and Infectious Diseases, National Institutes of Health
Melanie OttGladstone Institute of Virology, Gladstone Institutes
Melanie OttUniversity of California san francisco
Melanie OttUniversity of California san francisco
Satish K PillaiUniversity of California san francisco
Satish K PillaiVitalant Research Institute
Afam A OkoyeVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University
Warner C GreeneGladstone Institute of Virology, Gladstone Institutes
Warner C GreeneUniversity of California san francisco
Warner C GreeneUniversity of California san francisco
  • 1 - 48

Datasets